Moderna, Inc. (MRNA) stock analysis

Moderna, Inc. — Healthcare · Biotechnology carries a Plainview business-quality score of 5.0/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Moderna, Inc. shows trailing revenue of $2.23B, a 18.8% gross margin, net cash of $6.32B, a loss per share of -7.95, valued at about 25.8x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $143.97
• YTD Return: +366.5%
• Revenue TTM: $2.23B
• Revenue Trend: YoY +2.1%
• Gross Margin: 18.8%
• Net Cash: $6.32B
• EPS: -7.95
• P/S Ratio: 25.8x

Compare: MRNA vs UNH · MRNA vs JNJ · MRNA vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, ABBV